Quick Answer
TG THERAPEUTICS, INC. reported Total Revenue of $616.29 million for the year ending 2025.
- TG THERAPEUTICS, INC. showed an increase of +87.3% in Total Revenue from 2024 to 2025.
- This data is from TG THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $38.0 thousand | Q3 2017: $38.0 thousand | Q1 2018: $38.0 thousand | Q2 2018: $38.0 thousand | Q3 2018: $38.0 thousand | Q1 2019: $38.0 thousand | Q2 2019: $38.0 thousand | Q3 2019: $38.0 thousand | Q1 2020: $38.0 thousand | Q2 2020: $38.0 thousand | Q3 2020: $38.0 thousand | Q1 2021: $793.0 thousand | Q2 2021: $1.55 million | Q3 2021: $2.03 million | Q1 2022: $2.02 million | Q1 2022: $2.02 million | Q2 2022: $594.0 thousand | Q2 2022: $594.0 thousand | Q3 2022: $94.0 thousand | Q3 2022: $94.0 thousand | Q1 2023: $7.80 million | Q2 2023: $16.07 million | Q3 2023: $165.82 million | Q1 2024: $63.47 million | Q2 2024: $73.47 million | Q3 2024: $83.88 million | Q1 2025: $120.86 million | Q2 2025: $141.15 million | Q3 2025: $161.71 million.
- Over the full 12 years of available data (2016 to 2025), TG THERAPEUTICS, INC.'s Total Revenue has grown by 405,352.0%.
- Historical annual values: Fiscal year 2025: $616.29 million | Fiscal year 2024: $329.00 million | Fiscal year 2023: $233.66 million | Fiscal year 2022: $2.79 million | Fiscal year 2022: $2.79 million | Fiscal year 2021: $6.69 million | Fiscal year 2021: $6.69 million | Fiscal year 2020: $152.0 thousand | Fiscal year 2019: $152.0 thousand | Fiscal year 2018: $152.0 thousand | Fiscal year 2017: $152.0 thousand | Fiscal year 2016: $152.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: